Xining
Xining
Xining, Qinghai, China60 results · Page 1 of 3
Clinical trials
Swipe the table sideways for more columns.
| Trial | Conditions | Status | Phase | Updated | More info | NCT ID |
|---|---|---|---|---|---|---|
| A Study to Confirm Safety and Efficacy of Lecanemab in Participants With Early Alzheimer's Disease | Alzheimer disease, Cognition Disorders, Cognitive Dysfunction, brain disorder, central nervous system disorder, cognitive disorder, dementia, nervous system disorder, neurodegenerative disease, psychiatric disorder, tauopathy | Active, not recruiting | Phase 3 | 2026-10-06 | NCT03887455 | |
| Clinical Trial of TQA3605 Tablet in Combination With Nucleos(t)Ide Analogues(NAs) Versus NAs Alone for the Treatment of Patients With Chronic Hepatitis B Virus Infection Who Have Undergone Treatment and Exhibit Low Viral Load or Poor Response | Blood-Borne Infections, Chronic Disease, DNA Virus Infections, Digestive System Diseases, Disease Attributes, Hepadnaviridae infectious disease, Hepatitis, Chronic, Infections, Pathologic Processes, Pathological Conditions, Signs and Symptoms, chronic hepatitis B virus infection, hepatitis, hepatitis B virus infection, infectious disease, liver disorder, viral hepatitis, viral infectious disease | Not yet recruiting | Phase 3 | 2026-10-02 | NCT07797231 | |
| A Study to Evaluate the Safety and Efficacy of Tacabrutideg (BGB-16673) Compared to Pirtobrutinib in Adults With Relapsed/Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma | B-cell chronic lymphocytic leukemia, Chronic Disease, Disease Attributes, Hemic and Lymphatic Diseases, Leukemia, B-Cell, Neoplasms by Histologic Type, Pathologic Processes, Pathological Conditions, Signs and Symptoms, hematologic disorder, immune system disorder, immunoproliferative disorder, leukemia, lymphatic system disorder, lymphoid leukemia, lymphoproliferative syndrome, neoplasm | Recruiting | Phase 3 | 2026-09-28 | NCT06973187 | |
| A Study of Zolbetuximab Together With Pembrolizumab and Chemotherapy in Adults With Gastric Cancer | Neoplasms by Histologic Type, adenocarcinoma, carcinoma, epithelial neoplasm, neoplasm | Recruiting | Phase 3 | 2026-09-24 | NCT06901531 | |
| Combined Intrathecal and Systemic Therapy With Trastuzumab Rezetecan for Leptomeningeal Metastases | Neoplasms by Site, central nervous system cancer, neoplasm, neoplastic meningitis, nervous system disorder, tumor of meninges | Not yet recruiting | Phase 2 | 2026-09-22 | NCT07833657 | |
| A Multi-Center Randomized Controlled Trial on the Impact of Disease Subtype-Based Active Video Education on Bowel Preparation Quality in Patients With Inflammatory Bowel Disease | Digestive System Diseases, digestive system disorder, gastroenteritis, inflammatory bowel disease, intestinal disorder | Recruiting | Not applicable | 2026-09-22 | NCT07582731 | |
| A Clinical Trial of TQH3906 Capsules in Adult Patients With Moderate to Severe Plaque Psoriasis | Skin Diseases, Papulosquamous, Skin and Connective Tissue Diseases, psoriasis, skin disorder | Recruiting | Phase 3 | 2026-09-09 | NCT07724366 | |
| Intravenous rhPro-UK Before Stroke Thrombectomy in the Extended Time Window (BRIDGE-PUK EXTEND) | Acute Ischemic Stroke, brain disorder, cardiovascular disorder, central nervous system disorder, cerebrovascular disorder, ischemic stroke, nervous system disorder, stroke disorder, vascular disorder | Recruiting | Phase 3 | 2026-09-09 | NCT07389460 | |
| AMBITION 7: A Research Study Investigating How Well Zenagamtide Lowers Blood Sugar and Body Weight Compared to Insulin Glargine in People With Type 2 Diabetes and Increased Risk of Diseases That Affect the Heart and Blood Vessels Treated With 1-3 Other Diabetes Medications | Nutritional and Metabolic Diseases, diabetes mellitus, endocrine system disorder, glucose metabolism disease, metabolic disease, type 2 diabetes mellitus | Recruiting | Phase 3 | 2026-09-01 | NCT07797335 | |
| A Study of ATG-022 Compared With Investigator's Choice of Treatment in Claudin 18.2-Positive Advanced Gastric or Gastroesophageal Junction Adenocarcinoma | Advanced Gastric or Gastroesophageal Junction Adenocarcinoma | Not yet recruiting | Phase 3 | 2026-08-31 | NCT07795346 | |
| A Study of BGB-16673 Compared to Investigator's Choice in Participants With Relapsed/Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma Previously Exposed to Covalent Bruton Tyrosine Kinase (BTK) Inhibitors | B-cell chronic lymphocytic leukemia, Chronic Disease, Disease Attributes, Hemic and Lymphatic Diseases, Leukemia, B-Cell, Neoplasms by Histologic Type, Pathologic Processes, Pathological Conditions, Signs and Symptoms, hematologic disorder, immune system disorder, immunoproliferative disorder, leukemia, lymphatic system disorder, lymphoid leukemia, lymphoproliferative syndrome, neoplasm | Active, not recruiting | Phase 3 | 2026-08-24 | NCT06970743 | |
| Plasma Exosome RNA to Diagnose Prostate Cancer | Genital Diseases, Male Urogenital Diseases, Neoplasms by Site, Pathologic Processes, Pathological Conditions, Signs and Symptoms, Urogenital Diseases, Urogenital Neoplasms, disease, male reproductive organ cancer, male reproductive system disorder, neoplasm, prostate cancer, prostate disorder | Enrolling by invitation | Not applicable | 2026-07-30 | NCT06604130 | |
| Effect of EIT-guided PEEP in ARDS Patients | Lung Injury, acute lung injury, lung disorder, respiratory system disorder | Recruiting | Not applicable | 2026-07-10 | NCT06990477 | |
| Electroacupuncture for Chemotherapy-Induced GI Symptom Clusters in Breast Cancer | Neoplasms by Site, Skin and Connective Tissue Diseases, breast disorder, breast neoplasm, neoplasm, skin disorder | Recruiting | Phase 3 | 2026-07-10 | NCT06952920 | |
| A Study of CS0159 in Patients With PBC With Inadequate Response or Intolerance to UDCA | Digestive System Diseases, Fibrosis, Pathologic Processes, Pathological Conditions, Signs and Symptoms, bile duct disorder, biliary tract disorder, cholestasis, cirrhosis of liver, intrahepatic cholestasis, liver disorder, primary biliary cholangitis | Recruiting | Phase 3 | 2026-07-08 | NCT07282353 | |
| PD1 Combined With Chemotherapy for Adjuvant Treatment of Gastric Cancer | Gastric or Esophagogastric Junction Adenocarcinoma | Active, not recruiting | Phase 3 | 2026-07-07 | NCT05180734 | |
| Clinical Study on the Efficacy and Safety of LM-302 Injection Combined With Tislelizumab and Tislelizumab Combined Chemotherapy for the Treatment of Gastric or Gastroesophageal Junction Adenocarcinoma. | Neoplasms by Histologic Type, adenocarcinoma, carcinoma, epithelial neoplasm, neoplasm | Recruiting | Phase 3 | 2026-06-25 | NCT07385703 | |
| Electroacupuncture for Preventing Chemotherapy-Induced Peripheral Neuropathy in Patients With Early-stage Cancer | nervous system disorder, neuromuscular disease, peripheral nervous system disorder | Not yet recruiting | Not applicable | 2026-06-23 | NCT07663396 | |
| Indomethacin vs Diclofenac for Preventing PEP | Digestive System Diseases, pancreas disorder, pancreatitis | Recruiting | Not applicable | 2026-06-15 | NCT07071441 | |
| Electroacupuncture for Preventing Chemotherapy-Induced Peripheral Neuropathy in Patients With Advanced Cancer | nervous system disorder, neuromuscular disease, peripheral nervous system disorder | Not yet recruiting | Not applicable | 2026-06-12 | NCT07644533 | |
| TQB2930 Injection for the Treatment of HER2-positive Advanced Breast Cancer | HER2-positive Advanced Breast Cancer | Recruiting | Phase 3 | 2026-06-03 | NCT07047365 | |
| A Multicenter, Phase 3 Study of IBI343 Monotherapy Versus Treatment of Investigator's Choice in Subjects With Previously Treated, Claudin (CLDN) 18.2-positive, HER2-negative, Gastric or Gastroesophageal Junction Adenocarcinoma (G-HOPE-001) | Unresectable or Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma | Active, not recruiting | Phase 3 | 2026-05-13 | NCT06238843 | |
| Study on the Efficacy and Safety of Mecobalamin in Preventing Taxane-related Peripheral Neuropathy | nervous system disorder, neuromuscular disease, peripheral nervous system disorder | Recruiting | Phase 3 | 2026-04-30 | NCT07423390 | |
| Serial PSMA PET for Therapy Monitoring in Clinically Significant Prostate Cancer | Genital Diseases, Male Urogenital Diseases, Neoplasms by Site, Urogenital Diseases, Urogenital Neoplasms, male reproductive organ cancer, male reproductive system disorder, neoplasm, prostate cancer, prostate disorder | Recruiting | Not stated | 2026-04-28 | NCT07553780 | |
| Olanzapine Plus Metoclopramide for the Prevention of Opioid-Induced Nausea and Vomiting | Nausea, Pathological Conditions, Signs and Symptoms, Signs and Symptoms, Signs and Symptoms, Digestive, Vomiting | Recruiting | Phase 3 | 2026-04-27 | NCT07208305 |